From Supply Chain To Value Chain: OPPI’s Matai On Moving ‘Up’ Amidst Winds Of Policy Change In India

Incoming director general of the Organisation of Pharmaceutical Producers of India discusses the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices could be focus in the coming year, Anil Matai adds.

Anil Matai, director general, Organization of Pharmaceutical Producers of India • Source: OPPI

The Organization of Pharmaceutical Producers of India (OPPI)’s new director general, Anil Matai, sees a distinct shift in the “tone” at the helm of the Indian drug regulatory apparatus – it’s one that is “talking science, research and innovation”.

“We are clearly seeing that directionally we're moving there, and that message is percolating down [the ranks] as well. We're getting positive signals that things are changing,” said Matai in a wide-ranging interview

While the bureaucracy has its task cut out, Matai also highlighted the Indian government’s intent around backing R&D and a clear

More from Manufacturing

More from Compliance